Spectrum Pharma slides after FDA raises concerns over lung cancer drug
20/09/2022 15:48
** Spectrum Pharmaceuticals Inc's SPPI.O shares fall
28.6%to $0.75, biggest one-day pct fall in over 6 months if
losses hold
** Among biggest pct losers across U.S. stock exchanges
** U.S. FDA in briefing document raises concerns over the
safety of SPPI's experimental cancer drug and questions the
benefits it provided over existing therapies urn:newsml:reuters.com:*:nL4N30R2ZW
** In November 2021, SPPI had submitted marketing
application for its drug candidate, poziotinib, to treat
patients with a form of non-small cell lung cancer
** Including session losses, company's shares down ~40% YTD
(Reporting by Khushi Mandowara)
((Khushi.Mandowara@thomsonreuters.com))
Recent news on Spectrum Pharmaceuticals
See all newsBrief: Assertio Holdings Announces Favorable Vote On Proposed Acquisition Of Spectrum Pharmaceuticals
Brief: Independent Proxy Advisory Firms ISS And Glass Lewis Recommend Spectrum Pharmaceuticals Stockholders Vote “For” Proposed Deal With Assertio Holdings, Inc.
Brief: Spectrum Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
U.S. RESEARCH ROUNDUP-CTI Biopharma, Park National, Playags
Spectrum Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary